Cargando…

Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR

Introduction: In-vivo quantification of the serotonin transporter (SERT) guided our understanding of many neuropsychiatric disorders. A recently introduced bolus plus constant infusion protocol has been shown to allow the reliable determination of SERT binding with reduced scan time. In this work, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Silberbauer, Leo R., Gryglewski, Gregor, Berroterán-Infante, Neydher, Rischka, Lucas, Vanicek, Thomas, Pichler, Verena, Hienert, Marius, Kautzky, Alexander, Philippe, Cecile, Godbersen, Godber M., Vraka, Chrysoula, James, Gregory M., Wadsak, Wolfgang, Mitterhauser, Markus, Hacker, Marcus, Kasper, Siegfried, Hahn, Andreas, Lanzenberger, Rupert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639732/
https://www.ncbi.nlm.nih.gov/pubmed/31354428
http://dx.doi.org/10.3389/fnmol.2019.00172
_version_ 1783436519753646080
author Silberbauer, Leo R.
Gryglewski, Gregor
Berroterán-Infante, Neydher
Rischka, Lucas
Vanicek, Thomas
Pichler, Verena
Hienert, Marius
Kautzky, Alexander
Philippe, Cecile
Godbersen, Godber M.
Vraka, Chrysoula
James, Gregory M.
Wadsak, Wolfgang
Mitterhauser, Markus
Hacker, Marcus
Kasper, Siegfried
Hahn, Andreas
Lanzenberger, Rupert
author_facet Silberbauer, Leo R.
Gryglewski, Gregor
Berroterán-Infante, Neydher
Rischka, Lucas
Vanicek, Thomas
Pichler, Verena
Hienert, Marius
Kautzky, Alexander
Philippe, Cecile
Godbersen, Godber M.
Vraka, Chrysoula
James, Gregory M.
Wadsak, Wolfgang
Mitterhauser, Markus
Hacker, Marcus
Kasper, Siegfried
Hahn, Andreas
Lanzenberger, Rupert
author_sort Silberbauer, Leo R.
collection PubMed
description Introduction: In-vivo quantification of the serotonin transporter (SERT) guided our understanding of many neuropsychiatric disorders. A recently introduced bolus plus constant infusion protocol has been shown to allow the reliable determination of SERT binding with reduced scan time. In this work, the outcomes of two methods, a bolus injection paradigm on a GE PET camera, and a bolus plus infusion paradigm on a combined Siemens PET/MR camera were compared. Methods: A total of seven healthy subjects underwent paired PET and paired PET/MR scans each with intravenous double-blind application of 7.5 mg citalopram or saline in a randomized cross-over study design. While PET scans were performed according to standard protocols and non-displaceable binding potentials (BP(ND)) were calculated using the multi-linear reference tissue model, during PET/MR measurements [(11)C]DASB was applied as bolus plus constant infusion, and BP(ND) was calculated using the steady state method and data acquired at tracer equilibrium. Occupancies were calculated as the relative decrease in BP(ND) between saline and citalopram scans. Results: During placebo scans, a mean difference in BP(ND) of −0.08 (−11.71%) across all ROIs was found between methods. PET/MR scans resulted in higher BP(ND) estimates than PET scans in all ROIs except the midbrain. A mean difference of −0.19 (−109.40%) across all ROIs between methods was observed for citalopram scans. PET/MR scans resulted in higher BP(ND) estimates than PET scans in all ROIs. For occupancy, a mean difference of 23.12% (21.91%) was observed across all ROIs. PET/MR scans resulted in lower occupancy compared to PET scans in all ROIs except the temporal cortex. While for placebo, BP(ND) of high-binding regions (thalamus and striatum) exhibited moderate reliability (ICC = 0.66), during citalopram scans ICC decreased (0.36–0.46). However, reliability for occupancy remained high (0.57–0.82). Conclusion: Here, we demonstrated the feasibility of reliable and non-invasive SERT quantification using a [(11)C]DASB bolus plus constant infusion protocol at a hybrid PET/MR scanner, which might facilitate future pharmacological imaging studies. Highest agreement with established methods for quantification of occupancy and SERT BP(ND) at baseline was observed in subcortical high-binding regions.
format Online
Article
Text
id pubmed-6639732
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66397322019-07-26 Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR Silberbauer, Leo R. Gryglewski, Gregor Berroterán-Infante, Neydher Rischka, Lucas Vanicek, Thomas Pichler, Verena Hienert, Marius Kautzky, Alexander Philippe, Cecile Godbersen, Godber M. Vraka, Chrysoula James, Gregory M. Wadsak, Wolfgang Mitterhauser, Markus Hacker, Marcus Kasper, Siegfried Hahn, Andreas Lanzenberger, Rupert Front Mol Neurosci Neuroscience Introduction: In-vivo quantification of the serotonin transporter (SERT) guided our understanding of many neuropsychiatric disorders. A recently introduced bolus plus constant infusion protocol has been shown to allow the reliable determination of SERT binding with reduced scan time. In this work, the outcomes of two methods, a bolus injection paradigm on a GE PET camera, and a bolus plus infusion paradigm on a combined Siemens PET/MR camera were compared. Methods: A total of seven healthy subjects underwent paired PET and paired PET/MR scans each with intravenous double-blind application of 7.5 mg citalopram or saline in a randomized cross-over study design. While PET scans were performed according to standard protocols and non-displaceable binding potentials (BP(ND)) were calculated using the multi-linear reference tissue model, during PET/MR measurements [(11)C]DASB was applied as bolus plus constant infusion, and BP(ND) was calculated using the steady state method and data acquired at tracer equilibrium. Occupancies were calculated as the relative decrease in BP(ND) between saline and citalopram scans. Results: During placebo scans, a mean difference in BP(ND) of −0.08 (−11.71%) across all ROIs was found between methods. PET/MR scans resulted in higher BP(ND) estimates than PET scans in all ROIs except the midbrain. A mean difference of −0.19 (−109.40%) across all ROIs between methods was observed for citalopram scans. PET/MR scans resulted in higher BP(ND) estimates than PET scans in all ROIs. For occupancy, a mean difference of 23.12% (21.91%) was observed across all ROIs. PET/MR scans resulted in lower occupancy compared to PET scans in all ROIs except the temporal cortex. While for placebo, BP(ND) of high-binding regions (thalamus and striatum) exhibited moderate reliability (ICC = 0.66), during citalopram scans ICC decreased (0.36–0.46). However, reliability for occupancy remained high (0.57–0.82). Conclusion: Here, we demonstrated the feasibility of reliable and non-invasive SERT quantification using a [(11)C]DASB bolus plus constant infusion protocol at a hybrid PET/MR scanner, which might facilitate future pharmacological imaging studies. Highest agreement with established methods for quantification of occupancy and SERT BP(ND) at baseline was observed in subcortical high-binding regions. Frontiers Media S.A. 2019-07-12 /pmc/articles/PMC6639732/ /pubmed/31354428 http://dx.doi.org/10.3389/fnmol.2019.00172 Text en Copyright © 2019 Silberbauer, Gryglewski, Berroterán-Infante, Rischka, Vanicek, Pichler, Hienert, Kautzky, Philippe, Godbersen, Vraka, James, Wadsak, Mitterhauser, Hacker, Kasper, Hahn and Lanzenberger. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Silberbauer, Leo R.
Gryglewski, Gregor
Berroterán-Infante, Neydher
Rischka, Lucas
Vanicek, Thomas
Pichler, Verena
Hienert, Marius
Kautzky, Alexander
Philippe, Cecile
Godbersen, Godber M.
Vraka, Chrysoula
James, Gregory M.
Wadsak, Wolfgang
Mitterhauser, Markus
Hacker, Marcus
Kasper, Siegfried
Hahn, Andreas
Lanzenberger, Rupert
Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR
title Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR
title_full Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR
title_fullStr Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR
title_full_unstemmed Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR
title_short Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR
title_sort serotonin transporter binding in the human brain after pharmacological challenge measured using pet and pet/mr
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639732/
https://www.ncbi.nlm.nih.gov/pubmed/31354428
http://dx.doi.org/10.3389/fnmol.2019.00172
work_keys_str_mv AT silberbauerleor serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT gryglewskigregor serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT berroteraninfanteneydher serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT rischkalucas serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT vanicekthomas serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT pichlerverena serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT hienertmarius serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT kautzkyalexander serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT philippececile serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT godbersengodberm serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT vrakachrysoula serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT jamesgregorym serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT wadsakwolfgang serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT mitterhausermarkus serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT hackermarcus serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT kaspersiegfried serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT hahnandreas serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr
AT lanzenbergerrupert serotonintransporterbindinginthehumanbrainafterpharmacologicalchallengemeasuredusingpetandpetmr